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PELVIC ORGAN PROLAPSE 
Pelvic organ prolapse (hereafter, simply referred to as prolapse) is defined as 
descent of the anterior or posterior vaginal wall, the uterus, or the vaginal vault (after 
hysterectomy).1 The different types of prolapse, which may co-exist, are summarized 
in Figure 1. Although the aetiology of prolapse is still not completely understood, loss 
of support of the pelvic organs, due to pelvic floor damage or weakness, is thought 
to play a major role (Box 1). The most consistent risk factors for prolapse are vaginal 
childbirth, higher parity, advanced age, obesity, and prior hysterectomy. Other obstetric 
factors like forceps delivery, prolonged second stage of labour, and birth weight >4500 
grams seem to increase the risk, but caesarean delivery is not completely protective 
against developing prolapse. Several other factors are also implicated, including 
risk factors like smoking, hormone replacement therapy, and comorbidities (mainly 
when associated with increased abdominal pressure; e.g., constipation or pulmonary 
disease); in addition, pelvic floor factors like defects of the levator ani muscle have 
also been implicated, though as yet, evidence for this is inconclusive. There is also 
growing evidence for a genetic component in the development of prolapse.2,3
Prolapse is common, its incidence and prevalence increasing with age.4,5 According 
to the Dutch General Practitioner Registration Network, the prevalence of prolapse in 
women aged 45 years and older varies between 0.8% and 2.7%,6 but a Dutch community 
survey of women aged 45–85 years showed a much higher prevalence, with some 12% 
of women reporting typical prolapse symptoms (seeing or feeling a vaginal bulge) and 
75% having some degree of prolapse on physical examination.7 Though it is true that 
many of these women might not consult their general practitioner, because they are 
either asymptomatic or only experience mild symptoms, many could avoid discussing 
prolapse with their general practitioner because of embarrassment or because they 
lack knowledge about prolapse, its symptoms, and the available treatment options.8 
Prolapse can lead to, or co-exist with, a variety of symptoms, and although the most 
typical symptom is vaginal bulging, many women are asymptomatic.5,7 Other prolapse 
symptoms include pelvic pressure, low backache, and the need to replace the prolapse 
digitally or to otherwise apply manual pressure to the vagina, perineum, or perianal 
area to assist voiding or defecation (i.e., “splinting”). Prolapse can lead to abnormal 
vaginal bleeding, discharge, or infection if there is ulceration of the prolapsed tissue. 
Prolapse may co-exist with lower urinary tract symptoms, including urinary frequency, 
incomplete bladder emptying/urinary retention, slow urinary stream, recurrent urinary 
tract infections, and urinary incontinence. Moreover, symptoms of anorectal dysfunction 
may be present, such as incomplete defecation, rectal urgency, and post-defecation 







Symptomatic prolapse can negatively influence a woman’s daily activities and quality 
of life.10-12 Indeed, almost 75% of women with symptomatic prolapse encounter 
discomfort as a direct consequence of their prolapse during daily life, with evidence 
that physical activities were moderately to severely affected in 33% of women with a 
symptomatic prolapse.13 In addition, the presence of prolapse may negatively affect 
sexual functioning.14-16 Women with advanced prolapses, for example, report feeling 
less feminine and less physically or sexually attractive when compared with women 
who have normal pelvic support.12 Moreover, more than one-third of sexually active 
women with advanced prolapse indicate that their sexuality is affected by prolapse 
symptoms.17
DIAGNOSIS OF PROLAPSE
Prolapse is diagnosed by pelvic examination. The standard classification system 
for assessing prolapse is the Pelvic Organ Prolapse Quantification system (POP-Q) 
(Box 2). If a prolapse is present or if there are pelvic floor symptoms, the condition 
of the pelvic floor muscles should be assessed globally. Pelvic floor function can be 
assessed during pelvic examination in the supine position; for example, the tone and 
strength of the pelvic floor muscles can be assessed by asking the patient to contract 
the pelvic floor muscles around the examining fingers. Urodynamic or anorectal 
functional testing and imaging (ultrasound or magnetic resonance imaging of the 
pelvic floor) offer no additional value in the diagnosis of prolapse in general practice.18
FIGURE 1 TYPES OF PROLAPSE
A: Anterior wall prolapse; B: Posterior wall prolapse; C: Uterine prolapse; D Post-hysterectomy vault 





Pelvic organ support depends on an interaction between the pelvic floor 
muscles and the endopelvic fascia, a loose connective tissue network that 
suspends the pelvic organs (especially the vagina and the uterus) by attachment 
to the pelvis. The pelvic floor is the caudal border of both the abdominal and 
the pelvic cavity, and is a complex structure of muscles, including the levator 
ani, the coccygeus, the external anal sphincter, the striated urethral sphincter, 
and the deep and superficial perineal muscles (Figure 2). 
BOX 1 .  PELVIC ORGAN SUPPORT AND PELVIC ORGAN 
DESCENT
FIGURE 2 SUPERIOR VIEW OF THE FEMALE PELVIC FLOOR MUSCLES
(adapted from Larish and Kaveler19)
These pelvic floor muscles, especially the levator ani muscle, play an important 
role in supporting the pelvic organs. Normally, they maintain a constant resting 
tone to keep the pelvic floor closed and hold the pelvic organs in place, thereby 
relieving the strain on the connective tissue attachments of the endopelvic 
fascia. However, when the pelvic floor muscles are damaged or weakened, for 
example due to vaginal childbirth, the pelvic floor opens and the unsupported 
pelvic organs must be held in place by the endopelvic fascia. This damages the 
endopelvic fascia, which may ultimately fail to hold the vagina and uterus in place, 
resulting in prolapse. Sometimes, prolapse even develops in the context of normal 
pelvic floor muscles; in these cases, the connective tissue of the endopelvic 










MANAGEMENT OF PROLAPSE IN GENERAL PRACTICE
Prolapse can be treated conservatively by lifestyle advice, pelvic floor muscle 
training (PFMT), or vaginal pessary, with surgery usually reserved for more severe 
cases. Treatment choice therefore depends on the severity of the prolapse-related 
symptoms, and on the woman’s general health and preference.23,24 Specifically, 
referral to a urogynaecologist is indicated if a (recurrent) prolapse leads to severe 
symptoms, if conservative treatment fails, or if the patient prefers surgical treatment.25 
In the Netherlands, most women are treated conservatively in primary care, with 
approximately 9% referred to secondary care.26 To help women with a prolapse decide 
on their preferred management, general practitioners need to provide them with 
accurate information on the effectiveness of different treatments and on the natural 
course of prolapse if left untreated. 
The natural course of prolapse
In the past, the belief that prolapse was a progressive disease guided clinical practice 
such that women with asymptomatic early prolapse were frequently offered surgical 
correction to prevent progression.27 However, the few studies that have since examined 
the natural course of prolapse showed that the condition was non-progressive in most 
cases,27-30 seldom leading to life threatening problems. It is equally unknown whether 
treatment at an earlier stage is more effective than intervention after the onset of 
symptoms or after worsening of the prolapse.27 Therefore, watchful waiting might be 
a good option in women who are asymptomatic or experience only mild symptoms.
Lifestyle advice 
The Dutch gynaecologists’ prolapse guideline recommends giving lifestyle advice to 
all women with symptomatic prolapse,18 which includes losing weight, avoiding heavy 
lifting, and consuming healthy food (to reduce constipation). This recommendation 
is based on the supposed association between increased abdominal pressure and 
the occurrence of prolapse, but is not yet supported by evidence from interventional 
studies. Nevertheless, it might still be worthwhile giving lifestyle advice to women 
with prolapse because the recommendations are not harmful, and because they are 
consistent with best practice for general health promotion.
Pelvic floor muscle training 
There are two main hypotheses underlying how PFMT is effective in the prevention 
and treatment of prolapse: first, that descent of the pelvic floor is prevented by 




The POP-Q system is an objective, site-specific system for describing 
and staging prolapse, and has good inter- and intra-observer reliability.31,32 
It involves quantitative measurements of various points representing anterior, 
apical, and posterior vaginal prolapse to create a topographic map of the vagina. 
During examination, a Valsalva manoeuvre is performed and the maximum 
extent of prolapse is determined relative to the anterior–posterior plane of the 
hymen at each point. This measurement, in centimetres, is then transformed 
to an ordinal staging system (Figure 3), with the total POP-Q stage defined as 
the POP-Q stage of the most prolapsed compartment.
BOX 2 .  POP-Q SYSTEM
FIGURE 3 STAGES OF UTERINE PROLAPSE ACCORDING TO THE POP-Q 
SYSTEM  (adapted from Barber et al.9)
The POP-Q system uses the following ordinal staging system:
• Stage 0 – There is no prolapse
•  Stage 1 – The leading edge of the prolapse is >1 cm above the level of the 
hymen 
•  Stage 2 – The leading edge of the prolapse is between ≤1 cm proximal and 
≤1 cm distal to the hymen 
•  Stage 3 – The leading edge of the prolapse is >1 cm distal to the hymen, but 
total eversion of the vagina has not occurred




Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
any increase in abdominal pressure; and second, that structural support of the pelvic 
floor can be built up by performing regular strength training over time.33 Previous 
studies, which were mainly performed in secondary and tertiary care, showed PFMT 
to be more effective in relieving prolapse symptoms when compared with a control 
intervention.34-45
Pessary treatment 
Vaginal pessaries are designed to support the prolapsing organs and limit the descent 
into the vagina (Figure 4). By relieving pressure on the supporting structures and 
pelvic organs, they may improve the symptoms of prolapse.46-55 Although pessaries 
are used as a first-line treatment for prolapse by 77% of gynaecologists in the United 
States,56 the evidence for their use mainly comes from observational and non-
randomized studies and the fact that they have very few contraindications. However, 
robust evidence on the long-term effectiveness and cost-effectiveness of pessary 
treatment is lacking, with most studies evaluating pessary treatment being performed 
in secondary or tertiary care. 
FIGURE 4 INSERTION OF A RING WITH SUPPORT PESSARY






Prolapse is one of the most common indications for gynaecological surgery among 
older women. The lifetime risk for prolapse surgery varies between 6% and 19%.58 In 
the Netherlands, the number of prolapse surgeries increased from 8,151 in 1997 to 
17,376 in 2009,59 and the cost of prolapse surgery performed by gynaecologists was 
approximately 50 million euros in 2013.60 Given the ageing population and the fact that 
prolapse is more common in the elderly, it is reasonable to assume that the costs of 
treating prolapse will increase over coming decades.58,61 In primary care, explanation 
of the benign nature and non-progressive course of prolapse might be satisfactory 
in many cases, especially for women who are not bothered by their prolapse or who 
only experience mild symptoms. However, when bothersome symptoms are present, 
conservative treatment should typically be applied because it causes far fewer side 
effects and complications than surgery. Providing this treatment in primary care 
ensures that therapy is generally less expensive, closer to a patients’ home, and 
easier to access compared with secondary care. However, there have been no high-
quality studies on the effectiveness of PFMT and pessary treatment in women with 
symptomatic prolapse in primary care. Indeed, the authors of a recent Cochrane 
review emphasized that there was an urgent need for randomized studies to compare 
the effectiveness of pessaries with other conservative measures.62 Thus, The Pelvic 
Organ Prolapse in Primary Care: Effects of Pelvic Floor Muscle Training and Pessary 
Treatment Study (POPPS) was designed to fill the knowledge gap regarding the 
conservative treatment of prolapse in primary care. 
THESIS OUTLINE
The POPPS trials were designed to investigate the effects and cost-effectiveness 
of conservative treatments for older women with symptomatic prolapse in a 
primary care population. In Chapter 2, the POPPS design is described in detail. 
This comprised two randomized controlled trials: in the first trial, women with 
a symptomatic mild prolapse (leading edge above the hymen) were randomly 
assigned to watchful waiting or PFMT (POPPS Trial 1); in the second trial, 
women with a symptomatic advanced prolapse (leading edge at or beyond the 
hymen) were randomly assigned to pessary treatment or PFMT (POPPS Trial 2). 
In Chapter 3, the effectiveness of the interventions in POPPS Trial 1 are compared after 
three months, and in Chapter 4, the effects and cost-effectiveness of the interventions 
are compared longitudinally for a two-year follow-up period. Then, in Chapter 5, the 




longitudinally for a two-year follow-up period. 
Community-dwelling women aged 55 years and older were actively approached to 
join the studies by a postal screening questionnaire, and women with one or more 
pelvic floor symptoms were invited for baseline assessment. The data collected 
at these assessments were used to investigate the predictors of sexual inactivity 
and of sexual functioning (in those who were sexually active) among older women 
with pelvic floor symptoms; the details of this are outlined in Chapter 6. Also using 
this baseline data, the discriminative abilities of anatomic cut-off points to identify 
clinically relevant prolapse, as established in specialist urogynaecology populations, 
are evaluated in Chapter 7.
When counselling women, it is important to know which factors are likely to predict 
a successful treatment outcome. Pessary fitting, for example, fails in a considerable 
portion of women, indicating that it is not suitable in all cases. In Chapter 8, the 
predictors of unsuccessful pessary fitting are described using the baseline data for 
women randomized to pessary treatment in POPPS Trial 2. Subsequently, using the 
data for all women randomized to PFMT from both trials, the factors that predict 
treatment success for prolapse in women undergoing PFMT are highlighted in Chapter 
9. In Chapter 10, the minimal important change in the PFDI-20, the questionnaire used 
to evaluate treatment effects in both trials, is discussed.
Finally, the thesis ends with a general discussion, in which the main findings and 
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